Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma
July 11, 2010 by admin · Leave a Comment
Findings by the John Theurer Cancer Center may lead to more targeted clinical trials and therapies
HACKENSACK, N.J. (July 12, 2010) A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE®), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib. Additionally, researchers demonstrate that biomarkers the genes and proteins that indicate biological processes might help guide the selection of patients for specific clinical trials and speed-up the development of targeted cancer drugs. The study, which is now published online, will also appear in the July issue of Leukemia & Lymphoma.
How to overcome resistance to 1 group of breast cancer drugs
June 6, 2010 by admin · Leave a Comment
Contact: Karen Honey
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
A team of researchers, led by Carlos Arteaga, at Vanderbilt University Medical Center, Nashville, has identified a mechanism by which human breast cancer cells can develop resistance to one group of drugs used to treat breast cancer, suggesting new approaches to treating the disease.
‘Scout scans’ map the way in non-Hodgkin’s lymphoma treatment
June 6, 2010 by admin · Leave a Comment
Molecular imaging is leading to more individualized and effective treatment for non-Hodgkins lymphoma by providing a map to guide the path of therapy
SALT LAKE CITYAccording to a study presented at SNM’s 57th Annual Meeting, molecular imaging can evaluate and optimize non-Hodgkin’s lymphoma therapy with Zevalin, a front-line radioimmunotherapy drug that uses a dose of radioactive material and mimics the body’s own immune response to target and kill cancer cells while sparing nearby healthy tissues.
Study identifies promising treatment for aggressive lymphoma
May 25, 2010 by admin · Leave a Comment
Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
CHICAGO — New research illustrates that some patients with transformed lymphoma showed “remarkable” response to lenalidomide, an oral drug with few side effects.
Treatment of Helicobacter pylori-negative gastric MALT lymphoma
May 6, 2010 by admin · Leave a Comment
Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Eradication of Helicobacter pylori (H. pylori) is a well-accepted initial therapy in cases of localized (stage ⅠE) low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with H. pylori infection. However, there are no treatment guidelines for the management of H. pylori-negative low-grade gastric MALT lymphoma.
‘Junk DNA’ drives cancer growth
May 1, 2010 by admin · Leave a Comment
Contact: Paula Gould
p.a.gould@leeds.ac.uk
44-113-343-8059
University of Leeds
Researchers from the University of Leeds, UK, the Charité University Medical School and the Max Delbrück Centre for Molecular Medicine (MDC) in Berlin, Germany, have discovered a new driving force behind cancer growth.
Vitamin K may protect against developing non-Hodgkin’s lymphoma, say Mayo Clinic researchers
April 18, 2010 by admin · Leave a Comment
Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
WASHINGTON In the first study of vitamin K and Non-Hodgkin lymphoma risk, researchers at the Mayo Clinic campus in Minnesota have found that people who have higher intakes of vitamin K from their diet have a lower risk of developing Non-Hodgkin lymphoma. Non-Hodgkin Lymphoma is a cancer of the immune system and is the most common hematologic malignancy in the United States.
New class of drug kills lymphoma cells
April 13, 2010 by admin · Leave a Comment
Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College Read more
Scientists discover compound that kills lymphoma cells
April 11, 2010 by admin · Leave a Comment
Contact: Jane Finlayson
jane.finlayson@uhn.on.ca
416-946-2846
University Health Network
An international research team co-led by the Ontario Cancer Institute (OCI) has discovered a compound that kills specific lymphoma cells a discovery that will accelerate developing targeted drugs to fight the most common form of non-Hodgkins lymphoma.
Seaweed extract may hold promise for non-Hodgkin’s lymphoma treatment
March 9, 2010 by admin · Leave a Comment
Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
DEAD SEA, Jordan Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010.
